1.Comparative Stndy on Concentration Determination of Valproic Acid in Human Serum by LC-MS/MS and EMIT
Hailang SHI ; Haidong WANG ; Xingfa SONG
China Pharmacy 2017;28(8):1049-1052
OBJECTIVE:To compare the difference in the concentration determination of valproie acid (VPA) in human serum by LC-MS/MS and EMIT.METHODS:Both LC-MS/MS and EMIT methods were applied to determine the serum concentration of VPA in 144 inpatients or outpatients.The paired t-test,Pearson correlation analysis,Bland-Altman deviation chart and other methods were used to evaluate the difference in the results of concentration determination.RESULTS:The results of LC-MS/MS method was pos itively correlated with that of EMIT method (r=0.924,P<0.05);the regression equation of them was cEMIT=0.920 7cLC.MS/MS-1.114 4 (r=0.924).Average serum concentrations of VPA determined by LC-MS/MS and EMIT were (49.9 ± 21.2) and (54.9 ± 21.3) μg/mL,with statistical significance (P<0.05).The serum concentration of VPA determined by EMIT was higher than that by LC-MS/MS 8.3 μg/mL,95% confidence interval was (-13.6,18.7).CONCLUSIONS:The serum concentration of VPA determined by LC-MS/MS and EMIT have high correlation.But the determination results still have certain difference,it is suggested to use same method for long term monitering.
2.A multicenter study of costs of drugs in rheumatoid arthritis in China
Xiuru WANG ; Yin SU ; Yuan AN ; Yunshan ZHOU ; Lizhi WANG ; Caihong WANG ; Xiaofeng LI ; Lina CHEN ; Ping ZHU ; Xin LU ; Guochun WANG ; Hongtao JIN ; Rong YANG ; Yongfu WANG ; Guangtao LI ; Zhuoli ZHANG ; Lin SUN ; Xiangyuan LIU ; Jiemei TAO ; Fengxiao ZHANG ; Jing YANG ; Zhenbin LI ; Meiqiu WEI ; Jinying LIN ; Rong SHU ; Liufu CUI ; Dan KE ; Xiaomin LIU ; Cong YE ; Shaoxian HU ; Hao LI ; Xiuyan YANG ; Bei LAI ; Ming GAO ; Cibo HUANG ; Lijun SONG ; Xingfa LI ; Zhanguo LI
Chinese Journal of Rheumatology 2010;14(6):368-372
Objective To describe the distribution of medication costs of rheumatoid arthritis patients, and to analyze the factors that may affect the costs. Methods Data were obtained from a 12-month retrospective investigation of patients with rheumatoid arthritis (RA) across China. Department of Rheuma-tology of 18 hospitals were randomly selected. The data about their social conditions, clinical conditions, medications associated with RA such as disease-modifying antirheumatic drugs (DMARDs), non -steroidal anti -inflammtory drugs (NSAIDs), steroids, biologic agents were collected, and the costs of drugs were calculated. A non-parameter test and multivariate logistic regression analysis were performed. Results Six hundred and forty six patients were enrolled into the study, 435 completed data were chosen for analysis. The results demonstrated that the average costs per patient for medications in the past year was 8018 . The total medication costs were further subdivided into the following parts: DMARDs, (represented 20% of the total costs), biologic drugs (49%), NSAIDs (4%), herbal drugs (22%), steroids (1%). Data analysis showed that patients with higher education and higher incomes, with medical insurance,better health function status and outpatients paid more on DMARDs. Extra-articular manifestations increased the odds of the high-cost group (OR: 2.180, 95%CI: 1.335~3.558, P=0.002), while poor health function status increased the probability of paying high costs (OR: 1.373, 95%CI: 1.012~1.863, P=0.041). Conclusion High medication costs in RA do exist in RA patients. The costs of medication is associated with health function status and the presence of extra-articular manifestations.
3.Predictive value of isoform -2 proprostate-specific antigen and its derived indexes for prostate cancer patients with PSA 4-20 ng/mL
Huiru LU ; Liang LIANG ; Hongjun XIE ; Jian HU ; Qian ZHANG ; Zhandong SONG ; Jin HOU ; Ge TIAN ; Xingfa CHEN ; Lei LI
Journal of Modern Urology 2023;28(4):347-350
【Objective】 To evaluate the predictive value of isoform [-2] proprostate-specific antigen, p2 PSA (p2PSA) and its derived indexes for prostate cancer in a Chinese cohort with PSA 4-20 ng/mL. 【Methods】 A total of 139 males scheduled for biopsy were enrolled in the prospective study from Nov.2021 to Jun.2022. The total PSA (tPSA), free PSA (fPSA), fPSA/tPSA (f/t) and p2PSA were collected, and the percentage of p2PSA(%p2PSA) and prostate health index(PHI) were calculated. The predictive value of p2PSA and its derived indexes were compared with traditional indexes with receiver operating characteristic (ROC) curve and Logistic analysis. 【Results】 Prostate cancer was found in 54 cases (38.8%). There were significant statistical differences in tPSA(10.68 vs.8.14, P=0.021), f/t(0.13 vs.0.16, P=0.006), p2PSA(30.25 vs.19.81, P<0.001), %p2PSA(21.52 vs.13.15, P<0.001) and PHI(64.3vs.38.2, P<0.001) between prostate cancer patients and non-prostate cancer patients. The area under the ROC curve (AUC) of tPSA, fPSA, %fPSA, p2PSA, %p2PSA and PHI were 0.63, 0.51, 0.63, 0.71, 0.73, and 0.80, respectively. The inclusion of %p2PSA and PHI significantly increased the prediction efficiency of the basic prediction model (AUC